Ovarian Clinical Trials

716 recruitingLast updated: June 18, 2026

There are 716 actively recruiting ovarian clinical trials across 64 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Phase 4, Early Phase 1. Top locations include Houston, Texas, United States, New York, New York, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Ovarian Trials at a Glance

716 actively recruiting trials for ovarian are listed on ClinicalTrialsFinder across 6 cities in 64 countries. The largest study group is Phase 2 with 213 trials, with the heaviest enrollment activity in Houston, New York, and Boston. Lead sponsors running ovarian studies include National Cancer Institute (NCI), M.D. Anderson Cancer Center, and AstraZeneca.

Treatments under study

About Ovarian Clinical Trials

Looking for clinical trials for Ovarian? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Ovarian trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Ovarian clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 716 trials

Recruiting
Phase 1Phase 2

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

Breast CancerOvarian CancerEndometrial Cancer+2 more
AstraZeneca460 enrolled67 locationsNCT05123482
Recruiting
Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled479 locationsNCT05564377
Recruiting
Phase 2Phase 3

Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)

Gastric CancersColorectal, CancerPancreatic Ductal Adenocarcinoma+1 more
GE Healthcare175 enrolled2 locationsNCT07219238
Recruiting
Phase 2

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

Recurrent Ovarian CarcinomaRecurrent Endometrial CarcinomaRecurrent Fallopian Tube Carcinoma+1 more
National Cancer Institute (NCI)165 enrolled296 locationsNCT05554328
Recruiting
Phase 2

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Colorectal, CancerGastric CancerBiliary Tract Cancer+4 more
AstraZeneca454 enrolled96 locationsNCT05489211
Recruiting
Phase 1

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

Ovarian NeoplasmsStomach NeoplasmsLung Neoplasms+5 more
National Cancer Institute (NCI)100 enrolled1 locationNCT06885697
Recruiting
Phase 2

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Primary Peritoneal CancerFallopian Tube CancerNeoadjuvant+1 more
AbbVie140 enrolled66 locationsNCT06890338
Recruiting
Not Applicable

Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians

Ovarian CarcinomaPsychiatric Disorder
Fred Hutchinson Cancer Center25 enrolled1 locationNCT07282158
Recruiting
Phase 2

ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer

Recurrent Ovarian CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal Carcinoma+7 more
Ira Winer62 enrolled2 locationsNCT04055649
Recruiting
Phase 1

Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

Ovarian CancerOvarian CarcinomaPlatinum Resistant Ovarian Cancer+4 more
Dana-Farber Cancer Institute18 enrolled2 locationsNCT06321484
Recruiting
Not Applicable

To Evaluate the Safety of Autologous Tumor-infiltrating Lymphocytes(TILs) for the Treatment of Recurrent Ovarian Cancer

Recurrent Ovarian Cancer
Yong Wha Moon6 enrolled1 locationNCT07651124
Recruiting

Familial Investigations of Childhood Cancer Predisposition

Pancreatic CancerHereditary Breast and Ovarian CancerHodgkin Lymphoma+43 more
St. Jude Children's Research Hospital1,500 enrolled1 locationNCT03050268
Recruiting
Not Applicable

Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer

Ovarian CancerOvarian CarcinomaOvarian Neoplasms
Dana-Farber Cancer Institute112 enrolled1 locationNCT06543537
Recruiting
Phase 2

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

Ovarian Cancer
AbbVie400 enrolled73 locationsNCT07059845
Recruiting
Not Applicable

ASk Questions in GYnecologic Oncology (ASQ-GYO)

Ovarian CancerCervical CancerEndometrial Cancer+3 more
Ira Winer70 enrolled1 locationNCT06339827
Recruiting
Phase 1

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Triple-Negative Breast CancerPancreatic CancerNon-small Cell Lung Cancer+4 more
AbbVie694 enrolled46 locationsNCT05005403
Recruiting
Phase 1

A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

Endometrial CancerTesticular CancerPlatinum Resistant Ovarian Cancer
Context Therapeutics Inc.156 enrolled14 locationsNCT06515613
Recruiting

DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study

Pleuropulmonary BlastomaCystic NephromaNasal Chondromesenchymal Hamartoma+2 more
National Cancer Institute (NCI)1,500 enrolled2 locationsNCT01247597
Recruiting
Phase 3

Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency

Premature Ovarian Insufficiency
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)185 enrolled1 locationNCT06851754
Recruiting

Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires

Systemic Lupus Erythematosus (SLE)Primary Ovarian Insufficiency (Poi)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)100 enrolled1 locationNCT05567198